Xeris Biopharma Holdings, Inc. XERS Total Liabilities & Equity
Total Liabilities & Equity at other companies
Other financials
Where this comes from
Reported directly by Xeris Biopharma Holdings, Inc. in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.
The official record: Xeris Biopharma Holdings, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Xeris Biopharma Holdings, Inc.'s total liabilities & equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Xeris Biopharma Holdings, Inc.'s total liabilities & equity?
- Xeris Biopharma Holdings, Inc. (XERS) reported total liabilities & equity of $392.01M in Q1 2026.
- How has Xeris Biopharma Holdings, Inc.'s total liabilities & equity changed year-over-year?
- Xeris Biopharma Holdings, Inc.'s total liabilities & equity increased by 24.3% year-over-year, from $315.45M to $392.01M.
- What is the long-term trend for Xeris Biopharma Holdings, Inc.'s total liabilities & equity?
- Over 5 years (2020 to 2025), Xeris Biopharma Holdings, Inc.'s total liabilities & equity has grown at a 19.2% compound annual growth rate (CAGR), from $159.15M to $383.53M.
- What does total liabilities & equity mean?
- Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.